Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 545 participants across two phases. In Phase II, 43 people were assigned to placebo and 44 to nintedanib. In Phase III, 229 people were assigned to each group. The trial was looking at nintedanib (a type of cancer medicine) added to standard chemotherapy, compared to chemotherapy plus a placebo (an inactive treatment), in people with a type of lung cancer. The main thing being measured was how long people lived without their cancer getting worse — called "progression-free survival" — and a key secondary measure was how long people lived overall. The reported data shows that in the Phase II part of the trial, the placebo group had a median progression-free survival (meaning half the group reached this point) of 5.72 months, while the nintedanib group had 9.36 months. In the larger Phase III part, the reported figures were 6.97 months for placebo and 6.77 months for nintedanib. For overall survival — how long people lived from the start of the trial — the Phase II results showed 14.46 months for placebo and 18.30 months for nintedanib, while Phase III showed 16.07 months for placebo and 14.36 months for nintedanib. These numbers represent the midpoint (median) for each group, meaning half the participants in each group lived longer than this and half did not reach it. For the Phase III part only, the reported data also shows that about 42.8% of people in the placebo group and 45.0% in the nintedanib group had their tumour shrink by a meaningful amount (called an "objective response"). Additionally, 92.6% of the placebo group and 90.8% of the nintedanib group had their disease either shrink or stay stable for at least 36 days (called "disease control"). These numbers describe what was observed and recorded in the trial. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 31103412) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Mesothelioma Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of cancer called malignant pleural mesothelioma (MPM), confirmed by a tissue sample, and your specific subtype is either "epithelioid" or "biphasic" (or only "epithelioid" depending on which part of the trial you would join)
- Your doctor believes you are likely to live for at least 3 more months
- You are in relatively good physical condition, able to carry out normal daily activities with little or no difficulty (measured by a standard health scale called ECOG, scoring 0 or 1)
- Your cancer can be measured using medical scans, according to specific measurement guidelines used in this trial
Who may not be able to join:
- You have previously had chemotherapy treatment for your mesothelioma
- You have previously been treated with a drug called nintedanib, or have received any other prior cancer treatment
- Your mesothelioma is of the "sarcomatoid" subtype, or in some cases the "biphasic" subtype (confirm with trial site for which part of the trial applies to you)
- You are experiencing troublesome nerve problems, such as pain, numbness, or weakness (symptomatic neuropathy)
- You have had radiotherapy (other than to the arms or legs) within the 3 months before your first scans for this trial
- You have cancer that has spread to your brain and has not been stable for at least 4 weeks
- Your scans show that your tumour has hollow or dead areas inside it, or that the cancer is growing into major blood vessels
- You have significant heart or blood vessel problems
- Your blood tests show that your blood, kidneys, or liver are not working well enough (confirm specific levels with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Boehringer Ingelheim, Boehringer Ingelheim
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.